Fig. 2. Resistance to S63845-induced apoptosis through loss of BAK or elevated BCL-XL. Resistance to S63845-induced apoptosis through loss of BAK or elevated.

Slides:

Advertisements

Similar presentations

PI3K inhibition does not Effect the BH3 Profile of SW620 Cells

Advertisements

Volume 24, Issue 1, Pages (July 2013)

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

S55746 synergizes with panobinostat in vitro and in vivo in DLBCL

Merkel Cell Carcinoma Dependence on Bcl-2 Family Members for Survival

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

BET inhibition and depletion repress the expression of BRCA1 and RAD51

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Figure S1 Nil + CK Nil CK C BIM BCLXL Pro-caspase 3 Cleaved caspase 3

Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.

Volume 12, Issue 5, Pages (November 2007)

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 4. Functional annotation of VUS in EGFR.

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Volume 24, Issue 1, Pages (July 2013)

Synergistic effect of S63845 with lapatinib, trastuzumab, or docetaxel

Fig. 1. PARPi and MEKi induce inverse adaptive responses.

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

MRSA virulence proteins cause LMC death and diminished CLV function

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 3. Wisper controls CF behavior and survival.

Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse.

Volume 16, Issue 5, Pages (December 2004)

Fig. 5. Perturbations of AHR-STUB1-TF axis normalize the hyperthrombotic uremic phenotype without altering the bleeding risk. Perturbations of AHR-STUB1-TF.

Fig. 4. MATE1 transcription in RCC.

NF1 downregulation activates MAPK pathway signaling.

Figure 1. A CRISPR/Cas9 synthetic lethal screen with PRMT5 inhibitor EPZ in H2171 cell line. (A) A pie chart ... Figure 1. A CRISPR/Cas9 synthetic.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 7. Inhibitory mechanisms of C12G6.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 1. β-APP overexpression or exposure to inflammatory mediators induces sIBM-like pathology in cultured rat myocytes that is abrogated by arimoclomol.

Volume 17, Issue 12, Pages (December 2016)

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Volume 12, Issue 5, Pages (November 2007)

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 5. Induction of apoptosis via enhanced BCL-2 dependence in FLT3-ITD+ AML cells with diverse coexisting somatic mutations by in vivo kinase inhibition.

Fig. 3 CSF1 is expressed in human melanoma.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 2. Cellular response to FolamiRs in vitro.

Fig. 1. Specificity of FolamiR uptake in cancer cells in culture.

JAK2 knockdown abrogates tumorsphere expansion after chemotherapy

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 4 ALRN-6924 inhibits cellular proliferation and clonogenic capacity, and induces cell cycle arrest and apoptosis in AML cell lines. ALRN-6924 inhibits.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Volume 8, Issue 5, Pages (September 2014)

Effect of M-cadherin RNAi and GSK-3β inhibition on myogenic differentiation of C2C12 myoblasts. Effect of M-cadherin RNAi and GSK-3β inhibition on myogenic.

CD151-knockdown cells show an aberrant spreading response to PMA

Bcl-2 and bcl-xL Antisense Oligonucleotides Induce Apoptosis in Melanoma Cells of Different Clinical Stages Robert A. Olie, Christoph Hafner, Renzo Küttel,

Effect of GSK-3β inhibition on cell-confluence-induced apoptosis.

CCG regulates cellular localization and blocks target gene expression of MRTF. A, SK-Mel-147 cells were cotransfected with RhoC and the SRE.L reporter.

Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

Fig. 2. Cellular response to FolamiRs in vitro.

Presentation transcript:

Fig. 2. Resistance to S63845-induced apoptosis through loss of BAK or elevated BCL-XL. Resistance to S63845-induced apoptosis through loss of BAK or elevated BCL-XL. (A) SK-BR-3 cells were infected with a genome-wide lentiviral sgRNA library and treated with S63845 (1 μM) or DMSO control, and then gDNA of surviving cells was isolated to identify the sgRNAs by NGS. The pooled analysis from six independent infections, displaying normalized values for S63845 or DMSO control, is shown. Solid red bar represents the regression line. The sgBAK1 hits are shown as blue dots. See table S5 for top up-regulated sgRNAs in the S63845-treated pools. (B) SK-BR-3 cells infected with CRISPR-Cas9 guides targeting proapoptotic proteins were treated with increasing concentrations of S63845 for 24 hours before assessment of viability using CellTiter-Glo. Ev, empty vector. (C) SK-BR-3 cells infected with CRISPR-Cas9 guides targeting BIM, BID, and PUMA were treated with increasing concentrations of S63845, as described above. (D) The MDA-MB-468 cell line was treated with increasing concentrations of S63845 in the presence of ABT-199, WEHI-539, or ABT-737 (500 nM) for 24 hours before assessment of viability using CellTiter-Glo. For (B) to (D), means ± SEM for three independent experiments are shown. (E) PDX tumor cells were cultured for 24 hours in mammosphere medium with ABT-199, ABT-737, WEHI-539, and S63845 (500 nM and 1 μM) or combination treatment with S63845 and other BH3 mimetics (both at 500 nM) before assessment of viability using CellTiter-Glo. Results are presented as percentages of untreated cells. Bars represent means ± SEM for at least five independent experiments per PDX. The tumor subtype for each PDX is shown in parentheses. Delphine Merino et al., Sci Transl Med 2017;9:eaam7049 Published by AAAS